<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093545</url>
  </required_header>
  <id_info>
    <org_study_id>Si178/2015</org_study_id>
    <nct_id>NCT03093545</nct_id>
  </id_info>
  <brief_title>Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients</brief_title>
  <official_title>Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VINS Bioproducts Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogentech Co.,LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, prospective cohort, open-label study of rabies post exposure program with
      equine rabies immunoglobulin (ERIG) and purified chick-embryo cell (PCEC) rabies vaccine in
      WHO category III exposed patients at Siriraj Hospital, Thailand aims to compare serum RVNA
      responses between obese (BMI &gt; 30 kg/m2) and normal weight/underweight (BMI &lt; 25 kg/m2) and
      to evaluate adverse events occurring after immunization on days 7, 14 and 28.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, prospective cohort, open-label study of rabies post exposure program with
      equine rabies immunoglobulin (ERIG) and purified chick-embryo cell (PCEC) rabies vaccine in
      WHO category III exposed patients at Siriraj Hospital, Thailand aims to compare serum RVNA
      responses between obese (BMI &gt; 30 kg/m2) and normal weight/underweight (BMI &lt; 25 kg/m2) and
      to evaluate adverse events occurring after immunization on days 7, 14 and 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of rabies virus neutralizing antibody (RVNA) levels between obese and normal/underweight patients.</measure>
    <time_frame>At day 7 prior to vaccination.</time_frame>
    <description>To compare RVNA levels between obese and normal/underweight patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference of rabies virus neutralizing antibody (RVNA) levels between obese and normal/underweight patients.</measure>
    <time_frame>At day 14 prior to vaccination.</time_frame>
    <description>To compare RVNA levels between obese and normal/underweight patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference of rabies virus neutralizing antibody (RVNA) levels between obese and normal/underweight patients.</measure>
    <time_frame>At day 28 prior to vaccination.</time_frame>
    <description>To compare RVNA levels between obese and normal/underweight patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>From day 0 to day 60</time_frame>
    <description>Number of participants with ERIG or PCEC-related adverse events as assessed by investigator as per CTCAE v4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Normal BMI or underweight (&lt; 24 Kg/m2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese (BMI &gt; 30 Kg/m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Equine Rabies Immunoglobulin</intervention_name>
    <description>40 IU per kg of body weight of ERIG at Day 0</description>
    <arm_group_label>Normal BMI or underweight (&lt; 24 Kg/m2)</arm_group_label>
    <arm_group_label>Obese (BMI &gt; 30 Kg/m2)</arm_group_label>
    <other_name>ERIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified chick-embryo cell rabies vaccine</intervention_name>
    <description>1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.</description>
    <arm_group_label>Normal BMI or underweight (&lt; 24 Kg/m2)</arm_group_label>
    <arm_group_label>Obese (BMI &gt; 30 Kg/m2)</arm_group_label>
    <other_name>PCEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ages of &gt;= 18 years and older;

          2. Experienced WHO category III rabies exposure excluding presenting wound at eye(s) or
             eye lid(s);

          3. Either a) obese with BMI &gt;= 30 or b) normal weight and/or underweight with BMI &lt; 25;

          4. Agree to independently consent to participate in all study procedures.

        Exclusion Criteria:

          1. Positive skin test to ERIG or known hypersensitivity to ERIG or its excipients;

          2. Co-enrolment with other studies or participated in other investigational drug studies
             or use of other investigational drugs within 4 weeks or five times the half-life of
             the investigational drug;

          3. Female patients who are currently pregnant or breast feeding.

          4. Presenting with wound at eye(s) or eye lid(s);

          5. Receiving rabies vaccination more than 7 days for this exposure;

          6. History of complete pre-exposure or post-exposure regimen with at least 3 doses;

          7. Known of allergic to egg or poultry meat;

          8. History of previous exposure to equine sera

          9. Significant illness that might harm or increase the risk to the patients;

         10. History of drug abuse or alcoholism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Jatuporn Sirikun</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>rabies</keyword>
  <keyword>obese</keyword>
  <keyword>immunoglobulin</keyword>
  <keyword>rabies vaccine</keyword>
  <keyword>post-exposure</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to provide individual participant data (IPD). However, other researcher could request IPD from principal investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

